Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Long-term results of mitral valve replacement with prosthesis «BioLAB»

Authors: R.M. Muratov, S.I. Babenko, N.N. Soboleva, A.S. Sachkov, L.A. Bockeria

Company:
A.N. Bakoulev Scientific Center for Cardiovascular Surgery, Ministry of Health of the Russia, Rublevskoe shosse, 135, Moscow, 121552, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.

Link: Clinical Physiology of Blood Circulaiton. 2015; (): -

Quote as: Muratov R.M., Babenko S.I., Soboleva N.N., Sachkov A.S., Bockeria L.A.. Long-term results of mitral valve replacement with prosthesis «BioLAB». Klinicheskaya Fiziologiya Krovoobrashcheniya (Clinical Physiology of Circulation, Russian journal). 2015; 4: 26-33 (in Russ.)

Download
Full text:  

Abstract

Objective – to analyze the results of implantation of xenopericardial bioprosthesis “BioLAB” in the mitral position at followup of 15 years.

Material and methods. From January 1993 to December 2008 were implanted 83 bioprosthesis of “BioLAB” in mitral valve position in 81 patients. The average age was 64.2±6.1 years (51–73 years). The main reason for the formation of heart disease was rheumatism in 63 (78%) patients. All patients were in NYHA class III and IV, 52 (64%) patients had permanent atrial fibrillation.

Results. 30-day mortality was 8,7% (n = 7). At the hospital stage were two redo’s, because of prosthetic dysfunction in the form of sagging flaps, and in cause of early prosthetic endocarditis development. The remaining patients were discharged in satisfactory condition. In the long-term period the fate of 67 patients was known, 6 patients were lost from observation for different reasons. 33 patients died for various reasons. Survival in up to 5, 10 and 15 years after surgery was 72.3 ± 5.6, 55.2 ± 6.6, 22.8 ± 12.1% respectively. Freedom from degeneration of bioprosthesis among survived patients was 73.3 ± 6.4% at 8 years, 65.2 ± 7.2% at 10 years and 50.2 ± 9.6% at 12 years. In the long-term period 14 redo’s were performed due to dysfunction of bioprosthesis. The average time before the second operation was 7.5 years (from 4 to 10 years). 4 (28%) patients died after reoperation during hospital stay.

Conclusions. Considering the life expectancy in the general population and the survival rate up to 15 years in our study it is possible to implant xenopericardial prosthesis of «BioLAB» in mitral valve position, in patients older than 75 years or earlier, if there is presence of absolute contraindications for receiving indirect anticoagulants. Improved methods of processing and creation of new biological tissues may allow us to recommend biological prostheses for the mitral position for younger patients in future.

References

  1. Zilla P., Human P., Bezuidenhout D. Bioprosthetic heart valves: the need for a quantum leap. Biotechnol. Appl. Biochem. 2004; 40 (Pt 1): 57–66.
  2. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 2005; 5: 685–94.
  3. Manji R.A., Zhu L.F., Nijjar N.K., Rayner D.C., Korbutt G.S., Churchill T.A. et al. Glutaraldehydefixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation. 2006; 114 (4): 318–27.
  4. Бабенко С.И., Муратов Р.М., Соболева Н.Н., Камолов С.Р., Бакулева Н.П., Бокерия Л.А. Протезирование митрального клапана ксенобиопротезом ≪БиоЛАБ≫: промежуточные результаты. Грудная и сердечно-сосудистая хирургия. 2008; 1: 23–7.
  5. Быкова В.А., Фурсов В.А., Цукерман Г.И., Малашенков А.И. Результаты протезирования митрального клапана ксеноперикардиальным биопротезом. Грудная и сердечно-сосудистая хирургия. 1990; 8: 16–9.
  6. Bourguignon T., Bouquiaux-Stablo A., Loardi C., Mirza A., Candolfi P., Marchand M. et al. Very late outcomes for mitral valve replacement with the Carpentier–Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. J. Thorac. Cardiovasc. Surg. 2014; 148: 2004–11.
  7. Jamieson W.R., Miyagishima R.T., Burr L.H., Lichtenstein S.V., Fradet G.J., Janusz M.T. Carpentier– Edwards porcine bioprostheses: clinical performance assessed by actual analysis. J. Heart Valve Dis. 2000; 9: 530–5.
  8. Ayegnon K.G., Aupart M., Bourguignon T., Mirza A., May M.A., Marchand M. A 25-year experience with Carpentier–Edwards perimount in the mitral position. Asian Cardiovasc. Thorac. Ann. 2011; 19: 14–9.
  9. Vahanian A., Baumgartner H., Bax J., Butchart E., Dion R., Filippatos G. et al. Guidelines on the management of valvular heart disease. Eur. Heart J. 2007; 28 (2): 230–68.
  10. Erdogˇan H.B., Kirali K., Rabus5 M., Erentugˇ V., Kayalar N., Bozbugˇa N. et al. Reoperation for bioprosthetic mitral valve dysfunction early and late-term risk analysis. Tьrk. Gцgˇьs Kalp. Damar. Cerrahisi Dergisi. 2006; 14 (3): 199–204.
  11. Jaussaud N., Gariboldi V., Grisoli D., Berbis J., Kerbaul F., Riberi A. et al. Risk of reoperation for mitral bioprosthesis dysfunction. Heart Valve Dis. 2012; 21 (1): 56–60.
  12. Dahm M.L., Lyman W.D., Schwell A.B., Factor S.M., Frater R.W. Immunogenicity of glutaraldehyde-tanned bovine pericardium. J. Thorac. Cardiovasc. Surg. 1990; 99 (6): 1082–90.
  13. Poulin L.F., Richard M., Le Moine A., Kiss R., McKenzie A.N., Goldman M. et al. Interleukin-9 promotes eosinophilic rejection of mouse heart allografts. Transplantation. 2003; 76: 572–7.
  14. Costa J.N.L., Pomerantzeff P.M.A., Braile D.M., Ramirez V.A., Goissis G., Stolf N.A.G. Comparaсao entre o pericárdio bovino decelularizado e o pericárdio bovino convencional utilizado na confecсao de biopróteses valvares cardсíacas. Rev. Bras. Cir. Cardiovasc. 2005; 20 (1): 14–22.

 If you found mistakes, select text and press Alt+A